Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) EBITDA Margin: 2011-2025

Historic EBITDA Margin for Fennec Pharmaceuticals (FENC) over the last 5 years, with Sep 2025 value amounting to -1.52%.

  • Fennec Pharmaceuticals' EBITDA Margin rose 7307.00% to -1.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -12.02%, marking a year-over-year decrease of 1543.00%. This contributed to the annual value of 5.40% for FY2024, which is 6550.00% up from last year.
  • Fennec Pharmaceuticals' EBITDA Margin amounted to -1.52% in Q3 2025, which was up 94.64% from -28.31% recorded in Q2 2025.
  • Fennec Pharmaceuticals' EBITDA Margin's 5-year high stood at 123,075.00% during Q1 2021, with a 5-year trough of -314.25% in Q1 2023.
  • In the last 3 years, Fennec Pharmaceuticals' EBITDA Margin had a median value of -18.67% in 2023 and averaged -57.23%.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' EBITDA Margin crashed by 11,696,121bps in 2022, and later soared by 36,841bps in 2024.
  • Fennec Pharmaceuticals' EBITDA Margin (Quarterly) stood at 7,587.27% in 2021, then plummeted by 94,946bps to 1,047.37% in 2022, then slumped by 106,605bps to -18.67% in 2023, then spiked by 689bps to -11.79% in 2024, then surged by 7,307bps to -1.52% in 2025.
  • Its EBITDA Margin stands at -1.52% for Q3 2025, versus -28.31% for Q2 2025 and -9.23% for Q1 2025.